Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Elixxer Ltd. V.QBA


Primary Symbol: V.ELXR

Healthcare Drug Manufacturers - Major
Elixxer Ltd is a Canada based company engaged in growing and producing medical-grade cannabis. It focuses on making investments in Nutraceuticals, Cosmetics, Pharma, and Cultivation and Extraction sectors.


TSXV:ELXR - Post by User

Elixxer Ltd. > Creso pharma in partnership with LGC News
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
Comment by rockmstockmon Jul 02, 2018 12:03am
170 Views
Post# 28258185

RE:Creso pharma in partnership with LGC News

RE:Creso pharma in partnership with LGC NewsPredicting 700 million $ in sales annually by 2022. LGC has just under 15% ownership maximum to foreign companies. That is 100million minus expenses for LGC
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities